Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MFN2 | O95140 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26108759 | 1.00 | MFN2 (0.49) | MFN2OPRM1AGTR2OPRK1OPRD1 | |
| SCHEMBL30645043 | 1.00 | MFN2 (0.49) | MFN2OPRM1AGTR2OPRK1OPRD1 | |
| SCHEMBL26510111 | 0.93 | MFN2 (0.46) | MFN2EPHX2HTTMEN1KMT2A | |
| SCHEMBL26112723 | 0.93 | MFN2 (0.46) | MFN2EPHX2HTTMEN1KMT2A | |
| SCHEMBL31187934 | 0.92 | MFN2 (0.46) | MFN2OPRM1AGTR2OPRK1OPRD1 | |
| SCHEMBL30645029 | 0.85 | ALDH1A1 (0.44) | MFN2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL26115455 | 0.85 | ALDH1A1 (0.44) | MFN2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL26112895 | 0.85 | ALDH1A1 (0.44) | MFN2MEN1KMT2AMAPK1LMNA | |
| SCHEMBL26509874 | 0.81 | MFN2 (0.63) | MFN2EPHX2HTTMEN1KMT2A | |
| SCHEMBL26114293 | 0.81 | MFN2 (0.63) | MFN2EPHX2HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332124-A1 | MITOFUSIN ACTIVATORS HAVING AN ENDOCYCLIC-BONDED CARBONYL GROUP AND METHODS FOR USE THEREOF | DORN II GERALD W (US) | 2025-10-30 | — | — | US | disclosed |
| US-12396968-B2 | Mitofusin activators having an endocyclic-bonded carbonyl group and methods for use thereof | DORN II GERALD W (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4504700-A1 | MITOFUSIN ACTIVATORS HAVING AN ENDOCYCLIC-BONDED CARBONYL GROUP AND METHODS FOR USE THEREOF | Dorn II, Gerald W. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-118922407-A | Mitochondrial fusion protein activators with inner loop-bonded carbonyl groups and methods of use thereof | 杰拉尔德·W·多恩二世 | 2024-11-08 | — | — | CN | disclosed |
| US-20240050386-A1 | MITOFUSIN ACTIVATORS HAVING AN ENDOCYCLIC-BONDED CARBONYL GROUP AND METHODS FOR USE THEREOF | DORN II GERALD W (US) | 2024-02-15 | — | — | US | disclosed |
| WO-2023196340-A1 | MITOFUSIN ACTIVATORS HAVING AN ENDOCYCLIC-BONDED CARBONYL GROUP AND METHODS FOR USE THEREOF | DORN II GERALD W (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196340-A1 | MITOFUSIN ACTIVATORS HAVING AN ENDOCYCLIC-BONDED CARBONYL GROUP AND METHODS FOR USE THEREOF | DORN II GERALD W (US) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12396968-B2 | Mitofusin activators having an endocyclic-bonded carbonyl group and methods for use thereof | MFN2, CYCS, CYC1 | MFN2 1/4885OPRM1 2112/4885AGTR2 2742/4885 |
| US-20240050386-A1 | MITOFUSIN ACTIVATORS HAVING AN ENDOCYCLIC-BONDED CARBONYL GROUP AND METHODS FOR USE THEREOF | MFN2, CYCS, CYC1 | MFN2 1/4885OPRM1 2112/4885AGTR2 2742/4885 |
| US-20250332124-A1 | MITOFUSIN ACTIVATORS HAVING AN ENDOCYCLIC-BONDED CARBONYL GROUP AND METHODS FOR USE THEREOF | MFN2, CYCS, CYC1 | MFN2 1/4885OPRM1 2191/4885AGTR2 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.